Database Query Results : , , RTK-RAS

RTK-RAS, RTK-RAS: Click to Expand ⟱
Source: TCGA
Type:
Dysregulation of RTK-RAS signaling is a key driver of tumorigenesis. Overexpression or mutation of RTKs can lead to aberrant activation of RAS, contributing to cancer development.
Due to their central role in cancer, both RTKs and RAS proteins are important targets for cancer therapies. Inhibitors targeting RTKs (e.g., EGFR inhibitors) and RAS (e.g., direct RAS inhibitors) are being developed and tested in clinical settings.


Scientific Papers found: Click to Expand⟱
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis

PI3K/Akt↓, 1,  

Cell Death

BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BID↑, 1,   Mcl-1↓, 1,  

Kinase & Signal Transduction

HER2/EBBR2↓, 1,   RTK-RAS↓, 1,  

DNA Damage & Repair

P53↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence

CDK1↓, 1,  

Angiogenesis & Vasculature

EGFR↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   NF-kB↓, 1,  

Clinical Biomarkers

EGFR↓, 1,   HER2/EBBR2↓, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RTK-RAS, RTK-RAS
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:277  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page